long intergenic non-protein coding RNA 1282Genealiases: []
Q-omics provides the consensus-scored LINC01282 profile across patient tissues and cancer cell-line models. LINC01282 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01282 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, LINC01282 RNA expression shows 6,702 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where LINC01282 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01282 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01282 survival associations across molecular data types. LINC01282 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01282 RNA expression–survival associations across cancer types. High LINC01282 expression shows unfavorable associations in KIRC, KICH, UVM, KIRP, BLCA and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01282 RNA expression.
This table summarizes LINC01282 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01282. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01282 shows lower tumor expression in LUAD and higher tumor expression in HNSC, THCA, UCEC and PRAD. The HNSC box plot shows higher LINC01282 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p < 0.001).
This table shows molecular features associated with LINC01282 in patient tissues and cancer cell lines. In patient samples, LINC01282 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
